Literature DB >> 19572944

Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors.

Youhua Xu1, Rongjian Zhang, Jie Chen, Qichun Zhang, Juejin Wang, Jue Hu, Xiaowei Guan, Lai Jin, Hong Fu, Bo Gui, Yuanyuan Guo, Shengnan Li.   

Abstract

BACKGROUND AND
PURPOSE: Urocortin is a locally expressed pro-inflammatory peptide. Here we have examined the effects of urocortin on sodium laurate-induced peripheral arterial vasculitis in rats, modelling the mechanisms of thromboangiitis obliterans (TAO). EXPERIMENTAL APPROACH: Peripheral vasculitis in rats was induced by sodium laurate and graded by gross appearance on the 12th day after injection. Histological changes in rat femoral arteries were assessed by histopathology and transmission electron microscopy. Blood cell counts, blood rheology, blood coagulation and plasma urocortin, thromboxane B(2), prostaglandin E(2) and soluble intercellular adhesion molecule-1 levels were measured. Expression of urocortin, corticotrophin-releasing factor (CRF(1/2)) receptors, cyclooxygenase (COX)-2 and intercellular adhesion molecule-1 (ICAM-1) at both mRNA and protein levels were determined by RT-PCR and Western blot. KEY
RESULTS: Rats showed grossly visible signs and symptoms of TAO on the 12th day after sodium laurate injection. In these rats, blood was in a hypercoagulable state; plasma urocortin, prostaglandin E(2) and soluble intercellular adhesion molecule-1 levels were elevated; and the expression of urocortin, CRF(1) and CRF(1alpha)-receptors, COX-2 and ICAM-1 in rat femoral arteries were markedly increased. Exogenous urocortin, given for 12 days after sodium laurate, exacerbated the hypercoagulable state and augmented expression of CRF(1alpha)-receptors, COX-2 and ICAM-1. These effects were abolished by a CRF(1)-receptor antagonist, NBI-27914, or a non-selective CRF-receptor antagonist, astressin, but not by the CRF(2)-receptor antagonist, antisauvagine-30, given with exogenous urocortin. CONCLUSION AND IMPLICATIONS: Urocortin exacerbated the hypercoagulable state and vasculitis in a model of TAO induced by sodium laurate in rats, via CRF(1)-receptors. COX-2 and ICAM-1 might also have contributed to this exacerbation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19572944      PMCID: PMC2765315          DOI: 10.1111/j.1476-5381.2009.00210.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

Review 1.  Thromboangiitis obliterans (Buerger's disease).

Authors:  J W Olin
Journal:  N Engl J Med       Date:  2000-09-21       Impact factor: 91.245

2.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

3.  Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells.

Authors:  K Ohnaka; K Numaguchi; T Yamakawa; T Inagami
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

4.  mRNA expression profiles for corticotrophin-releasing factor (CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues.

Authors:  S M Baigent; P J Lowry
Journal:  J Mol Endocrinol       Date:  2000-08       Impact factor: 5.098

5.  Urocortin ameliorates diabetic nephropathy in obese db/db mice.

Authors:  X Li; J Hu; R Zhang; X Sun; Q Zhang; X Guan; J Chen; Q Zhu; S Li
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

6.  Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides.

Authors:  Bhawanjit K Brar; Alon Chen; Marilyn H Perrin; Wylie Vale
Journal:  Endocrinology       Date:  2003-12-11       Impact factor: 4.736

7.  Molecular and functional characterization of novel CRFR1 isoforms from the skin.

Authors:  Alexander Pisarchik; Andrzej Slominski
Journal:  Eur J Biochem       Date:  2004-07

8.  Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2.

Authors:  Juejin Wang; Youhua Xu; Yinyan Xu; Huayuan Zhu; Rongjian Zhang; Guoxin Zhang; Shengnan Li
Journal:  Cancer Invest       Date:  2008-05       Impact factor: 2.176

9.  Enhanced expression of vascular cell adhesion molecule-1 by corticotrophin-releasing hormone contributes to progression of atherosclerosis in LDL receptor-deficient mice.

Authors:  Yuqing Wu; Rongjian Zhang; Chenghua Zhou; Youhua Xu; Xiaowei Guan; Jue Hu; Yinyan Xu; Shengnan Li
Journal:  Atherosclerosis       Date:  2008-06-13       Impact factor: 5.162

10.  Possible involvement of corticotropin-releasing factor receptor signaling on vascular inflammation.

Authors:  Yuri Inada; Keiichi Ikeda; Katsuyoshi Tojo; Masaya Sakamoto; Yuko Takada; Naoko Tajima
Journal:  Peptides       Date:  2008-11-05       Impact factor: 3.750

View more
  6 in total

1.  Effect of omega-3 fatty acids on haemostatic functions in urocortin-treated obese rats.

Authors:  Ahmed A El-Gendy; Amr M Abbas
Journal:  J Physiol Biochem       Date:  2014-07-26       Impact factor: 4.158

Review 2.  Corticotropin-releasing factor family and its receptors: pro-inflammatory or anti-inflammatory targets in the periphery?

Authors:  Huayuan Zhu; Juejin Wang; Jianyong Li; Shengnan Li
Journal:  Inflamm Res       Date:  2011-04-08       Impact factor: 4.575

3.  Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease.

Authors:  Keiichi Ikeda; Kouki Fujioka; Yoshinobu Manome; Katsuyoshi Tojo
Journal:  Int J Endocrinol       Date:  2012-04-03       Impact factor: 3.257

4.  Systemic administration of urocortin after intracerebral hemorrhage reduces neurological deficits and neuroinflammation in rats.

Authors:  Hock-Kean Liew; Cheng-Yoong Pang; Chih-Wei Hsu; Mei-Jen Wang; Ting-Yi Li; Hsiao-Fen Peng; Jon-Son Kuo; Jia-Yi Wang
Journal:  J Neuroinflammation       Date:  2012-01-19       Impact factor: 8.322

5.  Vasoprotective effects of urocortin 1 against atherosclerosis in vitro and in vivo.

Authors:  Akinori Hasegawa; Kengo Sato; Remina Shirai; Rena Watanabe; Keigo Yamamoto; Kaho Watanabe; Kyoko Nohtomi; Tsutomu Hirano; Takuya Watanabe
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

6.  Levistilide A Ameliorates NLRP3 Expression Involving the Syk-p38/JNK Pathway and Peripheral Obliterans in Rats.

Authors:  Huining Guo; Li Sun; Shuang Ling; Jin-Wen Xu
Journal:  Mediators Inflamm       Date:  2018-08-12       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.